Gynecologic Oncology Research and Practice | Home page: Your invitation to submit to Gynecologic Oncology Research and Practice

Gynecologic Oncology Research and Practice | Home page

Dear Prof CERASALE MORTEO,

I am delighted to let you know that Gynecologic Oncology Research and Practice is now fully indexed in PubMed and PubMed Central. Please find below a selection of articles from the journal. I hope you find them of interest and encourage you to submit your next manuscriptto the journal.

---

Featured Articles

REVIEW
Adenocarcinoma of Mullerian origin: review of pathogenesis, molecular biology, and emerging treatment paradigms
		Lauren Patterson Cobb, Stephanie Gaillard, Yihong Wang et al. Abstract   |  Full text   |  PDF

---

REVIEW
Immunotherapy in endometrial cancer - an evolving therapeutic paradigm
		Teresa C. Longoria and Ramez N. Eskander Abstract   |  Full text   |  PDF

---

RESEARCH
Safety and efficacy of salvage nano-particle albumin bound paclitaxel in recurrent cervical cancer: a feasibility study
		Lindsey E. Minion, Dana M. Chase, John H. Farley et al. Abstract   |  Full text   |  PDF

---

---

Journal Scope

Gynecologic Oncology Research and Practice is an open access, peer-reviewed journal publishing original research, reviews and reports on all cancers of the female reproductive system. Overseen by an expert international editorial board, the journal's open access, online format, provides a high-visibility forum for oncologists, scientists and health care providers to discuss and share laboratory and clinical findings.

---

Reasons to Publish with Us

•	In-depth peer review directed by eminent Editors-in-Chief
•	Prompt publication of your article upon acceptance
•	All articles indexed in PubMed and PubMed Central

---

---

Submit your manuscript

Register to receive the latest articles, straight to your inbox.

---

Best wishes,

Robert L Coleman, Thomas J Herzog and Bradley J Monk
Editors-in-Chief, Gynecologic Oncology Research and Practice

For further information or enquiries please contact Customer Services at:info@biomedcentral.com.

BioMed Central Ltd 

236 Gray's Inn Road, London, WC1X 8HB, 

United Kingdom.

1. REVIEW

   Surgical management of lung, liver and brain metastases from gynecological cancers: a literature review

   Neville F. Hacker and Archana Rao

   Published on: 17 June 2016
2. RESEARCH

   Long term follow-up of a phase II trial of multimodal therapy given in a “sandwich” method for stage III, IV, and recurrent endometrial cancer

   Michelle Glasgow, Rachel Isaksson Vogel, Jennifer Burgart, Peter Argenta, Kathryn Dusenbery and Melissa A. Geller

   Published on: 26 May 2016
3. CASE REPORT

   A long-term surviving patient with recurrent low-grade serous ovarian carcinoma treated with the MEK1/2 inhibitor, selumetinib

   Munetaka Takekuma, Kwong K. Wong and Robert L. Coleman

   Published on: 5 May 2016
4. RESEARCH

   Safety and efficacy of salvage nano-particle albumin bound paclitaxel in recurrent cervical cancer: a feasibility study

   Lindsey E. Minion, Dana M. Chase, John H. Farley, Lyndsay J. Willmott and Bradley J. Monk

   Published on: 14 April 2016
5. REVIEW

   New treatment option for ovarian cancer: PARP inhibitors

   Robert S. Meehan and Alice P. Chen

   Published on: 26 February 2016

View all articles

Editors' profiles

Dr Robert L Coleman, Editor-in-Chief

Robert L. Coleman, MD is the Ann Rife Cox Professor in Gynecology & Deputy Chair in the Department of Gynecologic Oncology & Reproductive Medicine at The University of Texas MD Anderson Cancer Center, where he also serves as Vice-Chair, Clinical Research. Dr Coleman’s research interests include novel therapeutics for gynecologic cancers, clinical trial development and statistical design. He serves on the NRG’s Ovarian and Developmental Therapeutics Committees, and is PI or co-PI for several prospective clinical trials. He currently is a co-project leader for the MDACC Ovarian SPORE, the MDACC Uterine SPORE, the Ovarian Cancer Research Fund, and CPRIT, each of which is sponsoring novel therapeutics trials in gynecologic cancers. Dr Coleman has authored or coauthored over 400 scientific publications, including over 180 peer-reviewed original research articles, numerous book chapters, monographs, invited articles and textbooks. Dr Coleman is President-Elect for the Society of Gynecologic Oncology, Secretary Treasurer for the International Gynecologic Cancer Society, and serves on the American Board of Obstetrics and Gynecology, Division of Gynecologic Oncology.

Dr Thomas Herzog, Editor-in-Chief

Dr Thomas Herzog is the Director of Gynecologic Oncology and the Physicians & Surgeons Endowed Professor of Clinical Gynecology and Obstetrics.  He is also the Clinical Director of the University of Cincinnati Cancer Institute. Previously, he was the Fellowship Director in Gynecologic Oncology for Columbia & Cornell. He has served as a Principal Investigator in a number of GOG trials with a special emphasis in ovarian and endometrial cancers. Dr Herzog has authored/co-authored over 225 peer-reviewed articles and lectures extensively. Dr Herzog has been on the leadership council of the Society of Gynecologic Oncology, the Foundation for Women´s Cancer, Board of Governors for the American College of Surgeons. In 2013, he was elected to the Board of the American Board of Obstetrics and Gynecology.

Dr Bradley J Monk, Editor-in-Chief

Dr Monk is currently Professor and Director in the Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Creighton University School of Medicine at St. Joseph´s Hospital and Medical Center in Phoenix, AZ. Dr Monk is also a Professor on the Clinical Scholar Track at the University of Arizona College of Medicine – Phoenix. Dr Monk´s research interests include chemotherapy to treat ovarian and cervical carcinoma; the etiology, biomarkers in gynecologic cancers; and quality of life in women with advanced ovarian cancer. He is on the Board of Directors for the Gynecologic Oncology Group (GOG) and is the Group´s Cervical and Vulvar Committee Chair. Dr Monk has authored more than 180 peer-reviewed articles along with 27 book chapters.